Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems

2018 ◽  
Vol 128 ◽  
pp. 84-100 ◽  
Author(s):  
Masatoshi Maeki ◽  
Niko Kimura ◽  
Yusuke Sato ◽  
Hideyoshi Harashima ◽  
Manabu Tokeshi
2016 ◽  
Vol 12 (5) ◽  
pp. 598-604 ◽  
Author(s):  
Tatiana N. Pashirova ◽  
Tatiana Andreani ◽  
Ana S. Macedo ◽  
Eliana B. Souto ◽  
Lucia Ya. Zakharova

Pharmaceutics ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 860
Author(s):  
Raneem Jnaidi ◽  
António José Almeida ◽  
Lídia M. Gonçalves

Glioblastoma multiforme (GBM) is the most common and malignant type of brain tumor. In fact, tumor recurrence usually appears a few months after surgical resection and chemotherapy, mainly due to many factors that make GBM treatment a real challenge, such as tumor location, heterogeneity, presence of the blood-brain barrier (BBB), and others. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) represent the most promising carriers for therapeutics delivery into the central nervous system (CNS) owing to their inherent ability to cross the BBB. In this review, we present the main challenges in GBM treatment, a description of SLNs and NLCs and their valuable role as drug carriers in GBM treatment, and finally, a detailed description of all modification strategies that aim to change composition of SLNs and NLCs to enhance treatment outcomes. This includes modification of SLNs and NLCs to improve crossing the BBB, reduced GBM cell resistance, target GBM cells selectively minimizing side effects, and modification strategies to enhance SLNs and NLCs nose-to-brain delivery. Finally, future perspectives on their use are also be discussed, to provide insight about all strategies with SLNs and NLCs formulation that could result in drug delivery systems for GBM treatment with highly effective theraputic and minimum undesirable effects.


2014 ◽  
Vol 195 ◽  
pp. 72-85 ◽  
Author(s):  
Roy van der Meel ◽  
Marcel H.A.M. Fens ◽  
Pieter Vader ◽  
Wouter W. van Solinge ◽  
Omolola Eniola-Adefeso ◽  
...  

2016 ◽  
Vol 10 (1) ◽  
pp. 85-95
Author(s):  
Tesfaye Gabriel

Background: Acne vulgaris (commonly called acne) is the most prevalent skin complication of different causes with a higher prevalence in adolescents. Topical administration is used as first-choice therapy in mild acne, whereas for moderate and severe acne, systemic administration is required in addition to topical therapy. Mechanisms by which treatments act are: normalizing shedding into the pore to prevent obstruction, destruction of P.acnes, suppression of inflammation, and hormonal management. Objective: This review focuses on the novel drug delivery systems displaying a strong ground for topical treatment of acne in order to enhance the therapeutic performance of the topical antiacne agents with improved patience compliance and a concomitant reduction in the side effects. Method: This literature review was obtained from electronic search on Pubmed, Google Scholars, Researchgate, Scimago, CABI, DOAJ, CiteFactor, GLOBAL HEALTH, Universal Impact Factor, Hinari among many others and also search was conducted on individual journals and manuals. Conclusion: Amongst various novel drug delivery systems, vesicular carriers like liposomes and niosomes, micro sponges, microemulsions, solid lipid nanoparticles, hydrogels, emulsifier-free formulations, fullerenes and aerosol foams have been reported as novel topical administration of antiacne drugs. Liposomes have been extensively explored and their ability to optimize and improve topical therapy has been proved by several clinical trials. Microemulsions, microsponges, solid lipid nanoparticles and hydrogels also exhibit a tremendous potential for commercialization.


Author(s):  
Mahsa Mazdaei ◽  
Kofi Asare-Addo

The application of nanotechnology indrug delivery systems (DDS) has been researched widely and seen an advancementover the past three decades. Since the 1970s, nanoparticles were primarilyutilised in vaccine deliveries and cancer chemotherapy. In more recent years,they have been found to hold promises for broader applications such as inproteins and therapeutic gene delivery systems. To date, there have been only ahandful of nanocarrier-loaded drugs commercialised into the pharmaceuticalmarket. More research is thus needed to facilitate a breakthrough of theseproducts into the current market. This mini-review mainly focuses on four typesof commonly utilised organic nanocarriers including micelles, compactpolymerics, solid-lipid nanoparticles and liposomal vesicles and discusses theprogress and some challenges associated with these nanoparticles (NP). 


Pharmaceutics ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 75 ◽  
Author(s):  
Joana Magalhães ◽  
Luise L. Chaves ◽  
Alexandre C. Vieira ◽  
Susana G. Santos ◽  
Marina Pinheiro ◽  
...  

This work aims to optimize and assess the potential use of lipid nanoparticles, namely nanostructured lipid carriers (NLCs), as drug delivery systems of rifapentine (RPT) for the treatment of tuberculosis (TB). A Box–Behnken design was used to increase drug encapsulation efficiency (EE) and loading capacity (LC) of RPT-loaded NLCs. The optimized nanoparticles were fully characterized, and their effect on cell viability was assessed. The quality-by-design approach allowed the optimization of RPT-loaded NLCs with improved EE and LC using the minimum of experiments. Analyses of variance were indicative of the validity of this model to optimize this nanodelivery system. The optimized NLCs had a mean diameter of 242 ± 9 nm, polydispersity index <0.2, and a highly negative zeta potential. EE values were higher than 80%, and differential scanning calorimetry analysis enabled the confirmation of the efficient encapsulation of RPT. Transmission electron microscopy analysis showed spherical nanoparticles, uniform in shape and diameter, with no visible aggregation. Stability studies indicated that NLCs were stable over time. No toxicity was observed in primary human macrophage viability for nanoparticles up to 1000 μg mL−1. Overall, the optimized NLCs are efficient carriers of RPT and should be considered for further testing as promising drug delivery systems to be used in TB treatment.


2018 ◽  
Vol 24 (21) ◽  
pp. 2508-2512
Author(s):  
Joana R. Campos ◽  
Ana R. Fernandes ◽  
Patricia Severino ◽  
Maria L. Gracia ◽  
Selma B. Souto ◽  
...  

Fats are essential nutrients that have a significant role in the human diet and are essential to provide energy. Fatty acids are present in several types of lipids, such as triglycerides and phospholipids. Fatty acids differ among them, depending on the number of double bonds and on the length of the hydrocarbon chains. If there are no double bonds, the fatty acids are considered saturated and show a linear structure. Compounds with double bonds are unsaturated and have bent structure. The saturated fatty acids are usually solid at room temperature and the unsaturated fatty acids are liquid at that very same temperature. These compounds are of recognized value as raw materials for drug delivery systems, such as lipid nanoparticles. The behaviour of the macroscopic aspects of fat polymorphisms is directly influenced by the melting point, the crystallization and their polymorphic transformations. In this work, we revise the most critical factors contributing for the long-term stability of lipid nanoparticles, as well as the influence of the polymorphism on the loading capacity for drug molecules.


Sign in / Sign up

Export Citation Format

Share Document